** Shares of Amplia Therapeutics ATX.AX rise as much as 16.3% to A$0.100, posting their biggest percentage gain since Oct. 10
** Stock hits its highest level since Nov. 15
** Drug developer reports positive clinical trial results for its pancreatic cancer drug narmafotinib
** Says 35% patients show partial response in trial vs 23% in historical standard-of-care treatment
** About 6.4 mln shares change hands, compared with the 30-day average volume of around 1.6 mln
** Stock up 20.7% YTD, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。